Press release
Primary Progressive MS – Strong pipeline in progressive MS indicates a paradigm shift in MS landscape
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.Primary progressive multiple sclerosis is primarily characterized by progression of disease activity and the disability amongst the patients. As per the latest report by Pharmascroll, PPMS- A Detailed Overview, nearly 10-15% of the multiple sclerosis patients are Primary Progressive MS patients. The Primary Progressive MS patients might have an active or non-active progression of disease.
As per the current scenario in Multiple Sclerosis indication, there are over 15 molecules approved in the worldwide market. However, majority of the molecules are approved in the Relapsing Remitting form of Multiple Sclerosis. The more progressive forms of Multiple Sclerosis like Primary Progressive MS and Secondary progressive MS are still to encounter the boom in terms of number of launched molecules and hence the indication sales revenue.
However, as per the report PPMS- A Detailed Overview, for Primary progressive MS, the scenario is changing rapidly. The launch of Ocrelizumab by Roche and Genentech in PPMS segment and a strong pipeline in PPMS including the products Laquinimod by Teva, Masitinib by AB Sciences, Lemtrada by Sanofi, Ibudilast by MediciNova and Idebenone by Santhera, indicates a huge paradigm shift for the progressive forms of MS specifically PPMS.
The report provides an overview of PPMS in detail, highlights the PPMS epidemiology in the key geographies (Forecast to 2024), elaborates on the drugs prescribed and expected to be prescribed in PPMS and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecasts till 2030.
Why Purchase the report:
The report would help the pharma companies understand the PPMS indication in detail, identify business opportunities for making short term and long term plans, understand the epidemiology of PPMS, identify the triggers of prescription for the physicians in PPMS and make companies aware of the existing and upcoming competition along with their expected sales revenues and patient numbers in key geographies.
Companies Covered:
Biogen
Novartis
Sanofi
Sanofi Genzyme
Genzyme
Active Biotech
Merck
Teva
Bayer
Actelion
Medday Pharmaceuticals
Abbvie
Santhera Pharmaceuticals
AB Sciences
Roche
Medicinova
Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada
Table of Content:
1. Multiple Sclerosis Definition
2. Types of MS
a. RRMS
b. SPMS
c. PPMS
d. PRMS
3. PPMS defined
4. Causes of PPMS
5. Profile of PPMS Patient
6. Symptoms of PPMS
7. Disease progression and impact on QoL
8. Disease Diagnosis
a. Disease diagnosis through symptoms
b. Disease diagnosis through medical tests
9. Disease Epidemiology in US, UK, Germany, Italy, France, Spain, Japan
10. Factors impacting a physician’s prescription decision
a. Efficacy
b. Tolerability and Safety
c. Monitoring Requirements
d. Pricing and Reimbursement
11.Disease Modifying Therapies for PPMS
a. Laquinimod
b. Ocrelizumab
c. Masitinib
d. Lemtrada
e. Qizenday
f. Ibudilast
g. Idebenone
12.Drug Attribute Analysis
13. Other Pipeline Products
14. PPMS Market Sizing
a. Brand wise sales and patient numbers worldwide
b. Brand wise value and patient numbers by key geographies/countries
c. Country wise value sales and patient shares for all brands
The report can be checked at www.pharmascroll.com/product/ppms-detailed-overview
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
Pharmascroll Research and Consulting Private Limited
Hi tech City,
Hyderabad
500084
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Progressive MS – Strong pipeline in progressive MS indicates a paradigm shift in MS landscape here
News-ID: 939037 • Views: …
More Releases from Pharmascroll Research and Consulting Private Limited
Pharmascroll offers Social Media Analytics services for Pharmaceutical and Healt …
Pharmascroll, a renowned Market Research and Business Consulting firm, has been offering research services to Healthcare and Pharmaceutical firms since over 3 years. Pharmascroll has published 70+ syndicated reports in multiple disease indications and has served 30+ market research clients in the Pharmaceutical and Healthcare domain. The firm has catered to customers across Global markets including US, Europe and Asian countries. The firm currently offers research services in the areas…

Pharmascroll offering Quality Healthcare and Pharmaceutical Market Research serv …
Pharmascroll, a Market Research and Consulting firm, has been a renowned Syndicated and customized research provider across the Healthcare and Pharmaceutical space. Pharmascroll has generated over 75 market research reports in multiple disease indications and has consulted and researched for several Global clients across multiple areas.
Global Market Research Industry exceeded 44 Bn USD in revenues in 2015 and around 14% of the market research revenues registered across the Globe…

Schizophrenia: Disease Insights & Market Forecasts to 2024 by Pharmascroll
“Schizophrenia: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Schizophrenia disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Schizophrenia, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.
Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada
Drugs…

Epilepsy: Disease Insights and Market Forecasts to 2024 by Pharmascroll
“Epilepsy: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Epilepsy, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.
Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada
Drugs…
More Releases for PPMS
Emerging Trends to Drive Primary Progressive Multiple Sclerosis (PPMS) Treatment …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for the treatment of primary progressive multiple sclerosis (ppms) has seen significant expansion in recent years. It is set to increase from $1.02 billion in 2024 to $1.16 billion in 2025,…
Primary Progressive Multiple Sclerosis Treatment Market Projected to Exhibit Gro …
The global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market has witnessed remarkable growth owing to several key factors, as outlined in a comprehensive research report released by Transparency Market Research. The report delves into the drivers, trends, and projections shaping the landscape of PPMS treatment across the globe.
The rise in the geriatric population coupled with a surge in the prevalence of PPMS worldwide has significantly impacted the market statistics in…
Charting a Prosperous Path: PPMS Treatment Market to Achieve Over US$ 3.2 Billio …
The global primary progressive multiple sclerosis (PPMS) treatment market has witnessed substantial growth in recent years, with projections indicating a promising outlook for the future. Characterized by the progressive deterioration of nerve cells' protective covering, PPMS presents unique challenges that require innovative solutions. This article delves into the key drivers, trends, players, and future prospects of the PPMS treatment market.
𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗮 𝘀𝗮𝗺𝗽𝗹𝗲 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲…
Physical Property Measurement System (PPMS) Market 2023- 2029 Global Insights by …
The Physical Property Measurement System (PPMS) market refers to the industry involved in the manufacturing, distribution, and sale of PPMS instruments and related services. PPMS is a sophisticated laboratory instrument used to measure various physical properties of materials at extremely low temperatures, high magnetic fields, and under different environmental conditions.
PPMS instruments are widely used in scientific research and development, particularly in fields such as materials science, condensed matter physics, chemistry,…
Primary Progressive Multiple Sclerosis Market Size, Share, Epidemiology, Drugs, …
DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS), historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To know more about Primary Progressive Multiple Sclerosis, Click here: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Primary Progressive Multiple…
Multiple Sclerosis Market - Opportunity Analysis & Industry Forecast, 2017-2023
Multiple sclerosis (MS) is an inflammatory disease of nervous system, which is also referred as disseminated sclerosis. Multiple sclerosis is progressed with disruption spinal cord and brain nerve cells, which results in loss of ability of the parts of the nervous system to communicate including various other mental, physical and psychiatric problems. Primary progressive multiple sclerosis (PPMS) is the type of multiple sclerosis in which neurological functions are steadily deteriorated…